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Oxidative stressThis study aimed to evaluate a microemulsion system (ME) containing phenobarbital in epilepsymodel induced
by pilocarpine in rats and to oxidative stress and histologic lesions in hippocampus. The microemulsion was
applied to the shaved back of Wistar rats. The animals were divided into the following groups: control group
(P400); ME50 40 mg/kg, topically-t.p.; ME100, 40 mg/kg, t.p.; EM50, 40 mg/kg, t.p.; phenobarbital solution
40mg/kg (PS), oral. After 60min, behavioral changes were evaluated for 1 h in themodel of epileptical crisis in-
duced by pilocarpine. Phenobarbital inmicroemulsion was able to increase the latency for status epilepticus (SE)
(p b 0.05), decrease the number of epileptical crisis (ME50: p b 0.001; ME100: p b 0.01) and decrease mortality
rate by 80% compared to P400. In EM50 and PS groups, deaths were decreased by 53.3% and 100% respectively.
The ME50 and ME100 groups were able to reduce oxidative stress in experimental animals when compared to
the P400. The microemulsion was still capable of reducing neuronal damage in the hippocampal areas. The re-
sults of this study come in an innovative way, demonstrating the ability of transdermal ME50 and ME100 to re-
duce pilocarpine-induced epileptical crisis, oxidative stress, besides neuronal damages.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy is a brain disorder caused by the brain enduring predisposi-
tion to generate epileptic crisis and by the neurobiological, cognitive,
psychosocial and social consequences of the condition characterized
by the occurrence of at least one crisis (Guilhoto et al., 2006). Approxi-
mately 50million peopleworldwide are living with epilepsy. According
to some literature data, the prevalence of this condition in Brazil can
vary from 5.4 to 36.8/per 1000 inhabitants (Gomes et al., 2002;
Kanashiro, 2006). Epilepsy is considered the second most frequent
cause of neurological disorder in young adults (Betting et al., 2003),
with an overall incidence of approximately 1% in children (Yacubian,
2002).
Several animal models of epilepsy are used to study the pathophys-
iology of the convulsive process and the antiepileptic activity of drugs in
pre-clinical evaluation (Freitas et al., 2006). The use of pilocarpine intal Neurochemistry Research,
rtela, s/n, 64049-550 Teresina,
).rodents is an optimal animal model of induced epileptical crisis, with
great similarities in functional impact and morphological changes to
the temporal lobe epilepsy in humans (Cavalheiro et al., 1987). An in-
crease in lipid peroxidation and in nitrite levels as well as decreased
levels of reduced glutathione (GSH) and excessive production of free
radicals have been observed during crisis induced by pilocarpine
(Freitas et al., 2005). This model has been successfully used to evaluate
the antiepileptic action of newdrugs (Scorza et al., 2009), aswell as new
drug delivery system (Moreno et al., 2011).
In the last decade amajor breakthrough in the treatment of epilepsy
including the discovery of new drugs, new formulations of old drugs,
vagal stimulation, ketogenic diet, as well as surgical treatment
has been observed (Betting et al., 2003). As a general strategy for the
treatment of majority of cases indicated for crisis control is the use of
drugs in monotherapy (Dalmora et al., 2010).
Among those drugs, phenobarbital is a barbiturate used to treat
different forms of pediatric epilepsy and status epilepticus, being con-
sidered ﬁrst line for the control of neonatal seizures (Djabri et al.,
2012). It presents advantages like low cost, broad spectrum of action
and ease of use (Dalmora et al., 2010). Phenobarbital is a centenary
drug and it is still considered the most cost-effective pharmacological
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Kwan, 2012).
It is one of the drugs of choice in the treatment of status epilepticus
and febrile seizures (Pastore et al., 2007). Phenytoin and/or benzodiaz-
epines are usually recommended as initial treatment of epileptic
seizures in general, butwhen these drugs fail to control seizures, pheno-
barbital is often used (Walton and Treiman, 1989). It has good oral
bioavailability, but may have ﬂuctuations in plasma levels in pediatric
patients. In addition, it may reduce bioavailability and makes a differ-
ence of up to 60% when compared to a parenteral route of administra-
tion (Touw et al., 2000; Yukawa et al., 2011). Furthermore, the narrow
therapeutic window of this antiepileptic is one of the aggravating
factors for the treatment of seizures, since a usual dose can lead its plas-
ma concentrations to toxic levels.
In the literature, there are several papers describing the study of
alternative formulations available in themarket for the drug phenobar-
bital. Among these formulations, there can be cited: suppositories
(Moolenaar et al., 1979); oral suspension (Yska et al., 2000; Morantes
et al., 2010); oral solution (Jelveghari and Nokhodchi, 2008); hydrogel
and emulsion for transdermal use (Odria et al., 2005). There are also
studies about new drug delivery system, such as skin penetration of
phenobarbital using iontophoresis (Djabri et al., 2012). Several studies
have been moving towards the implementation of innovative formula-
tions, such as microemulsions as a carrier for various drugs (El-Setouhy
and El-Ashmony, 2010; Damasceno et al., 2011; Meng and Hu, 2011).
The microemulsions are thermodynamically stable and nanosized
droplets of two immiscible liquids (usually oil and water) stabilized
by a surfactant ﬁlm composite, located in the oil/water interface sys-
tems (Oliveira et al., 2004). The microemulsion systems can promote
skin penetration of various drugs. In general, in transdermal administra-
tion, dermal penetration of drugs is limited as the skin is an important
biological barrier that leaves only a few substances to penetrate under
certain conditions. The use of the transdermal route offers advantages
in different circumstances compared to other routes of administration.
It avoids the adversities of oral route, it is painless, non-invasive and
easy to apply, and may increase, thus, patient adherence to the therapy
(Silva et al., 2009, 2010).
In view of the numerous advantages of transdermal administration
of phenobarbital incorporated into microemulsion, the aim of this
study was to evaluate a microemulsion system containing this antiepi-
leptic in epilepsy model induced by pilocarpine in rats and to measure
oxidative stress by biochemical markers and histologic lesions in brain
areas.
2. Materials and methods
2.1. Animals
Female Wistar rats (n = 8–15/group), weighing 180–240 g, were
purchased from the Central Animal Facility of the Center for Agricultural
Sciences of UFPI. These were housed in a roommaintained at 25 ± 1 °C
with an alternating of 12 h of light–dark cycle. The hairs of the dorsum
were removed in an area of 4 cm2 through electric shaver. All experi-
ments proposed were previously submitted for consideration by the
Ethics Committee on Animal Experimentation of UFPI (research n.
0102/12 approved on 10 Dec 2012).
2.2. Preparation of samples for treatment
Pilocarpine hydrochloride (Vegeﬂora, Brazil) was dissolved in puri-
ﬁed water (distilled water) to obtain a ﬁnal concentration of 4 mg/ml.
Phenobarbital (PharmaNostra, Brazil, Lot. N. 10083132B) was dissolved
in puriﬁed water with 1% polyssorbate 80 v/v (Vetec, Brazil).
The microemulsion was prepared by mixing cold capryl caproyl
macrogol-8 glyceride - labrasol® (Gattefosse, France), ethanol (Dynam-
ic, Brazil), isopropyl myristate (Synth, Brazil) and puriﬁed water(Millipore, Germany) under magnetic stirring (100 rpm). Constituents
were mixed in the following order, followed by stirring for 20 min be-
tween steps: 1. labrasol® and ethanol; 2. isopropylmyristate; 3. puriﬁed
water; 4. Phenobarbital. A drug was incorporated without heating in
concentrations of 50 mg/g (ME50) and 100 mg/g (ME100). In the
preparation of the emulsion with phenobarbital to 50 mg/g (EM50)
was used an self-emulsionant nonionic wax (PharmaNostra, Brazil),
methylparaben (Vetec, Brazil), propylparaben (Vetec, Brazil), propylene
glycol (Vetec, Brazil) and puriﬁed water (Millipore, Germany).
2.3. Behavioral study in pilocarpine-induced epilepsy model
An amount corresponding to 40 mg/kg of phenobarbital
microemulsion was applied to the shaved backs of Wistar rats. This
dose was tested and standardized according to data from previous
studies, being less than that which prevented motor seizures induced
by homocysteine thiolactone in an American study, with an ED50 of
47 mg/kg (Walton and Treiman, 1989).
The animals were divided into the following groups: control group
(P400); ME50 40 mg/kg, topically – t.p.; ME100 40 mg/kg, t.p.; EM50,
40mg/kg, t.p.; phenobarbital solution 40mg/kg (PS), oral, used as a ref-
erence group. After 60 min, the groups were treated with pilocarpine
400 mg/kg, intraperitoneally – i.p. (P400) and behavioral changes
were evaluated in 1 h and the number of deaths was recorded within
24 h after administration (Turski et al., 1989; Freitas et al., 2006).
The groups were placed in cages 30 cm × 30 cm to observe the
following behavioral parameters: peripheral cholinergic signs (PCS),
tremors, stereotyped movements (SM), seizures, status epilepticus
(SE) and number of survivors, latency installation of ﬁrst seizure and
the latency of development of SE. Drug doses used were standardized
prior to conducting this experimental protocol.
2.4. Evaluation of oxidative stress in rat hippocampus
At the end of the previous experiment, the animals were killed by
decapitation and the brains were dissected on ice with hippocampal
removal for the determination of the levels of lipid peroxidation, nitrite
and reduced GSH. The levels of thesemarkers in animalswhich received
only vehicle (not pilocarpine) were also evaluated.
2.5. Determination of lipid peroxidation and the content of nitrite
Lipid peroxidation was assessed by determining the levels of acid
reactive substances to thiobarbituric acid (TBARS) as previously de-
scribed by Draper and Hadley (1990). Homogenates were prepared by
10% (w/v) in sodium phosphate buffer 50 mM (pH 7.4) of the brain
area of the investigated animals (n = 8) of the following groups: vehi-
cle, (P400), ME50, ME100, EM50 and PS. The samples were incubated
with 10% trichloroacetic acid and 0.67% thiobarbituric acid for 60 min
in a water bath at 37°° C. After centrifugation, the absorbance of the
samples was determined at 535 nm. The results were expressed in
mmol malonaldehyde (MDA).g tissue−1 (Freitas et al., 2005).
The nitrite content in all groups (n= 10) was determined based on
the Griess reaction (Green et al., 1981). Homogenates of the hippocam-
pus were incubated with 10% Griess reagent at room temperature
for 10 min. The absorbances were determined shortly thereafter at
550 nm. The concentration of nitrite was determined using a standard
curve constructed with nitrite NaNO2. The results were expressed in
millimolar—mM (Freitas et al., 2005).
2.6. Determination of reduced GSH
The GSH content was determined with some modiﬁcation of the
technique described by Sedlak and Lindsay (1968). Homogenates at
10% of all groups (n = 8) were prepared in EDTA 0.02 M. The extent
of the reaction product formed from 5.5′thiobis (2-nitrobenzoic acid)
Table 2
Behavioral changes in the pretreatment of animals with phenobarbital in the presence of
PCS, SM and tremors and seizures induced by pilocarpine.
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of GSH was expressed in nanogram of GSH.g tissue −1 (Freitas et al.,
2005).Group % PCS % SM % Tremors
P400 100 86.6 100
ME50 + P400 100 66.7 100
ME100 + P400 100 66.7 100
EM50 + P400 100 80.0 100
PS + P400 100 66.7 100
PCS = peripheral cholinergic signs; SM= stereotyped movements; P400 = pilocarpine
400 mg/kg, i.p., n = 15; ME50 = microemulsion phenobarbital 50 mg/g, 40 mg/kg, t.p.,
n = 15; ME100 = Microemulsion phenobarbital 100 mg/g, 40 mg/kg, t.p., n = 15;
EM50 = emulsion phenobarbital 50 mg/g, 40 mg/kg, t.p., n = 15; PS = Phenobarbital
40 mg/kg, p.o., n = 15. p N 0.05 (Fisher's exact test). The results were expressed as
percentage (%) and mean ± standard error of the average. PCS: peripheral cholinergic2.7. Histopathological analysis
After undergoing seizures induced by pilocarpine, animals were
sacriﬁced for removal of the brain, being preserved in 10% fomaldeid
for making histological sections. Tissues were embedded in parafﬁn
and made cuts of 5 μm with mount in microscope lamina. Lesions in
the brain tissue in CA1 (Cornu Ammonis 1) and dentate gyrus regions
of the hippocampus were evaluated by light microscopy and images
were recorded at 100× magniﬁcation.signs; SM: stereotyped movements.3. Results
After intraperitoneal administration of pilocarpine 400 mg/kg, the
animals showed similar changes to increased cholinergic behavioral
stimulation such as piloerection, chromodacriorrea, tremors, diarrhea,
diuresis, salivation and SM of scratching, rearing (lift), chewing,
among others, which persisted for 10 to 15 min. These behavioral
changes progressed to motor seizures (Turski et al., 1989), which
were observed for 30 to 50 min and then progressed to SE.
After topical application of phenobarbital incorporated into
microemulsion, it was observed that there were changes in the param-
eters analyzed for seizures induced by pilocarpine in the P400 (Table 1).
The embedded phenobarbital at 50 mg/g in microemulsion (ME50), as
well as at 100 mg/g (ME100), were able to increase the latency for the
onset of ﬁrst seizure in relation to the P400 group (p b 0.05). There
was no change in latency for SE and death of the animals. When it
was incorporated in emulsion (EM50), phenobarbital did not increase
latency in any of the parameters analyzed. In oral administration, PS
group completely inhibited the installation of seizures with onset time
0 min for all parameters.
After transdermal administration at a dose of 40 mg/kg, the
microemulsion system containing phenobarbital was able to prevent
the development of seizures in 86.7% and 73.4% of the animals in the
groups receiving microemulsion, ME50 and ME100, respectively.
There was 80% of survivors in both groups, with a difference of 60%
inhibition of deaths in relation to P400 (Table 1). When using EM50,
phenobarbital decreased by 60% the development of epileptical crises,
with a difference of 26.7% and 13.4% for the groups ME50 and ME100,
respectively. EM50had a surviving rate of 53.3% (26.7% lower compared
to groups receivingmicroemulsion). In the group used as a reference for
testings, PS, any deaths among animals was not veriﬁed.
Animals that received phenobarbital showed reductions of SM
compared to P400 group, by 66.7%, 66.7%, 80% and 66.7% for ME50,
ME100, EM50 and PS groups, respectively (Table 2). However, this
result was not statistically signiﬁcant for all groups receiving phenobar-
bital compared to the P400 group for the Fisher test. No reduction of PCS
and tremors was observed for the P400 group.Table 1
Behavioral changes in the pretreatment of animals with phenobarbital in pilocarpine model of
Group Latency seizures (min) % Seizures
P400 17.77 ± 0.96 86.6
ME50 + P400 25.0 ± 3.5a 13.3⁎⁎⁎
ME100 + P400 24.5 ± 4.03a 26.6⁎⁎
EM50 + P400 23.17 ± 4.3 40.0⁎
PS + P400 0 0⁎⁎⁎
SE= status epilepticus; P400=pilocarpine 400mg/kg, ip, n=15;ME50=Microemulsion of p
of 100 mg/g, 40 mg/kg, t.p., n = 15; EM100= emulsion of phenobarbital of 50 mg/g, 40 mg/kg
P400 (ANOVA followed by t-Student–Newman–Keuls was tested as post hoc test). *p b0.05,
expressed as percentage (%) and the average ± standard error of the average.In the evaluation of oxidative stress in the hippocampus of rats
submitted to the pilocarpine epilepsy model, we determined the levels
of TBARS, nitrite and GSH using in vitro methods.
ME50, ME100 and PS groups were able to reduce by 45%, 27.2% and
43.3% the levels of TBARS per gram of tissue compared to P400, respec-
tively, with statistical signiﬁcance of p b 0.001 and p b 0.05 (Fig. 1).
ME50 group reduced TBARS more intensively than EM50, observing a
difference between these groups (p b 0.01) and PS (p b 0.01). The
ME50, M100 and PS groups present levels of this marker in a similar
way to the vehicle (p N 0.05). The EM50 group decreased TBARS by
only 10.1%, with p N 0.05 in relation to P400 and p b 0.001 in relation
to normal animals (vehicle).
Nitrite levels in the groups treated with microemulsion differ when
compared to the P400 group, with a reduction by 29.8% and 31.9%,
respectively, for ME50 and ME100, with p b 0.05 (Fig. 2). The same
was evident in the PS group, with a reduction of 33.5%. In EM50, the
levels of nitrite reduced by 16.6%, but this result was not signiﬁcant
with p N 0.05. ME50, ME100 and EM50 were similar to PS, with
p N 0.05. The vehicle group showed lower levels of nitrite in relation
to other groups.
GSH levelswere signiﬁcantly increased in allME50,ME100, EM50 and
PS groups, by 51.1% (p b 0.01), 51.7% (p b 0.01), 38.4% (p b0.05) and
54.5% (p b 0.01), respectively, compared to the P400 group (Fig. 3). The
study groups had similar levels of GSH maintenance of stocks regarding
the group P400, but smaller relative to the vehicle (p b 0.001). There
was a more pronounced consumption of GSH in EM50 group, which
showed a difference of 20.5% and 21.5% in the levels of this antioxidant
molecule in relation to groups ME50 and M100, respectively. However,
this result was statistically insigniﬁcant (p N 0.05).
In Fig. 4, the histopathological analysis of the hippocampus of
animals subjected to seizures induced by pilocarpine can be observed.
Clearly the ME50, ME100 and PS groups similarly reduced neuronal le-
sions in animals of group P400, with preservation of the cells in their
histofunctional characteristics (central nucleus, evident nucleolus and
cohesive cells). The EM50 group showed impairment of hippocampal
cells, with cell death, but less intense than P400,which presented sever-
al picnotic cells, vacuolation and degeneration.seizures in Wistar rats.
Latency SE (min) Latency death (min) % Survivors
23.18 ± 2.4 27.0 ± 2.7 20.0
26.0 ± 3.0 26.5 ± 3.5 80.0⁎⁎
28.25 ± 3.3 28.3 ± 0.33 80.0⁎⁎
26.2 ± 5.6 29.0 ± 5.7 53.3
0 0 100.0⁎⁎⁎
henobarbital of 50mg/g, 40mg/kg, t.p., n=15;ME100=Microemulsion of phenobarbital
, t.p., n = 15; PS= Phenobarbital 40 mg/kg, orally, n = 15. ap b 0.05 regarding the group
**p b0.01 and ***p b0.001 regarding group P400. Test exact of Fisher. The results were
Fig. 1. Biochemical changes in the levels of TBARS in rat hippocampus after seizures
induced by pilocarpine 400 mg/kg i.p. (n = 8). The animals were divided into groups:
vehicle (negative control, normal animals); P400 (pilocarpine 400 mg/kg, ip); ME50
(Microemulsion phenobarbital 50 mg/g, 40 mg/kg, tp) + P400; ME100 (microemulsion
phenobarbital 100 mg/g, 40 mg/kg, tp) + P400; EM50 (emulsion of phenobarbital
50 mg/g, 40 mg/kg, t.p.) + P400; PS (phenobarbital 40 mg/kg, v.o.) + P400. One-way
ANOVA, followed by t-Student–Newman–Keuls test as post hoc test. The results were
expressed as nmol of MDA/g of tissue.
Fig. 3. Biochemical changes in GSH levels in rat hippocampus after seizures induced by
pilocarpine 400 mg/kg i.p. (n = 8) animals were divided into groups: vehicle (negative
control, normal animals); P400 (pilocarpine 400mg/kg, ip);ME50 (Microemulsion pheno-
barbital 50mg/g, 40mg/kg, t.p.)+ P400;ME100 (microemulsion phenobarbital 100mg/g,
40 mg/kg, tp) + P400; EM50 (Emulsion phenobarbital 50 mg/g, 40 mg/kg, tp) + P400;
PS (phenobarbital 40 mg/kg, v.o.) + P400. One-way ANOVA followed by t-Student–
Newman–Keuls test as post hoc test. The results were expressed as mg/g tissue.
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When systemically administered to rats at a dose of 400 mg/kg, the
range of pilocarpine induced persistent behavioral changes is similar to
that described in the literature (Freitas et al., 2006), These were follow-
ed bymotor limbic seizures, which began after 20–30min and repeated
every 2–5 min, leading then to the SE (Cavalheiro et al., 1987).
Antiepileptic drugs are able to increase the latency for the installa-
tion of the ﬁrst seizures (Costa et al., 2012). In this study, ME50,
ME100 and PS groups increased the time for the installation of the
ﬁrst seizure when compared with the P400 (Table 1). The P400 group
showed a similar number of deaths to the work of Clifford et al.Fig. 2. Biochemical changes in the levels of nitrite in rat hippocampus after seizures
induced by pilocarpine 400 mg/kg i.p. (n = 10). Animals were divided into groups:
vehicle (negative control, normal animals); P400 (pilocarpine 400 mg/kg, ip);
ME50 (Microemulsion phenobarbital 50 mg/g, 40 mg/kg, t.p.) + P400; ME100
(microemulsion phenobarbital 100 mg/g, 40 mg/kg, tp) + P400; EM50 (Emulsion
phenobarbital 50 mg/g, 40 mg/kg, tp) + P400; PS (phenobarbital 40 mg/kg v.o.) + P400.
One-way ANOVA, followed by t-Student–Newman–Keuls test as post hoc test. The results
were expressed as mM.(1985),with 20%of survivalswithin 24 h after administration of pilocar-
pine. Therewas a signiﬁcant reduction of the number of deaths inME50
and ME100, with an inhibition for EM50 26.7% shorter than these
groups.
Drugs capable of causing inhibition mediated by GABA, such as
barbiturates, act through inhibition of voltage-dependent sodium
channels in certain neuronal synapses, and reduce or even cease the
seizures induced by cholinergic agonists such as pilocarpine (Freitas
et al., 2006). Activation of the GABAergic system does not interfere
with peripheral effects mediated by pilocarpine, similar to other drugs
that have GABAergic mediation such as diazepam and clonazepam
(Freitas et al., 2006; Freitas, 2011). Phenobarbital was not able to signif-
icantly alter the behavioral parameters of Table 2.
Oxidative stress is deﬁned as the increased production of free
radicals in tissues and it can dramatically alter neuronal function
during seizures (Dymond and Crandall, 1976). ME50 and ME100 re-
duced oxidative stress and neuronal injury in experimental animals
when compared to P400, as evidenced by decreased levels of
TBARS, nitrite, maintenance of GSH levels and lesions in rat hippo-
campus (Figs. 1–4).
Lipid peroxidation can be induced bymany chemical agents and it
is present in neuronal injuries, such as epilepsy (Flohe and Otting,
1984). Phenobarbital may be able to reduce neuronal discharges in
brain areas such as the hippocampus, as indirectly evidenced by
the reduction of the levels of oxidative stress markers, like the pro-
duction of derivatives of nitric oxide (NO). High levels of TBARS are
present under conditions of oxidative stress and they are assessed
by determining MDA (Draper and Hadley, 1990). Under normal
conditions, there is a balance between the production of NO and its
metabolites (nitrite and nitrate) and their elimination by the antiox-
idant defense system. In epileptic seizures induced by pilocarpine
there is increased formation of nitrite with increased oxidative stress
and neuronal damage (Kudin et al., 2004).
GSH is responsible for the elimination of reactive oxygen species
derived (ROS) (Halliwell, 1993). In cases of oxidative stress ROS
levels that exceed the capacity of GSH to scavenge free radicals,
there is an increase in the consumption of the antioxidant molecule
and a consequent reduction on their levels (Freitas et al., 2005), as
can be noted in the P400 group (Fig. 3). The administration of pheno-
barbital in all formulations administered was able to maintain high
stocks of GSH in the P400, with lower maintenance thereof in
EM50 (around 20% less).
Fig. 4.Histological analysis of CA1 and dentate gyrus of the hippocampus of rats submitted to pilocarpine-induced seizures. The curve of cell bodies represents the dentate gyrus. The ﬁrst
ﬁgure represents the hippocampus of an animal treatedwith vehicle. Note the difference between normal tissue and animal tissue of animals with larger lesions (P400).→: Cell bodies of
normal neurons; Δ: Neurons with cell degeneration;○: Neurons dead. 100×.
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showed typical histological neuronal damage induced by pilocarpine
(Nascimento, 2004), butME50 andME100 groups presented a reduction
of such lesions in the hippocampus (Fig. 4). This result corroborates the
ﬁndings on reduction in number of crisis, deaths and regulation of
markers of oxidative stress in the test animals, similar to the results of
the work by Liu et al. (2012) for baicaline. ME50, ME100 and PS results
are higher than the EM50 ones in reducing lesions in rat hippocampus,
whichdemonstrates a possibly neuroprotection derived from the reduc-
tion of discharges of epileptic neuronal (Pitkanen, 2002), crises as well
as from the reduction of oxidative stress in brain area evaluated (Tomé
et al., 2010).
The transdermal way has potential application for chronic drug
therapy, as the treatment of epilepsy. Some authors have suggested
that the transdermal route to phenobarbital (Djabri et al., 2012), is
similar to other psychoactive drugs, such as clonazepam, clonaze-
pam and bupropion (Puglia et al., 2001; Tsai et al., 2011). Bonina
et al. (1993) demonstrated the ability of this antiepileptic drug
to permeate through the skin layers of humans and animals, making
it a promising drug for transdermal delivery systems, such as
microemulsions.Microemulsions offer advantages over traditional formulations,
which typically have a low ability to solubilize lipophilic drugs, such as
gels. Microemulsions can promote hydration of the corneum stratum
and thus facilitate the permeation of drugs transdermally (Sabale and
Vora, 2012), and they may have better outcomes than a cream
(Aggarwal et al., 2013). In addition, microemulsions act as permeation
enhancers through the layers of the skin due to the small size of the
droplets, as well as its high content of surfactant that contributes to
the disruption of the lipids of the skin (Silva et al., 2010). Such surfac-
tants allow interaction with the stratum corneal through disruption of
the lipid bilayer and the permeability of the drug is facilitated
(Damasceno et al., 2011). Moreover, the nanosized droplets presented
in this microemulsion can play a key role in cutaneous penetration of
phenobarbital (data not shown).
The Labrasol® surfactant is a derivative of polyethylene glycol with
low dermal irritability and it has been used in various microemulsion
compositions with good transdermal permeation (Zhao et al., 2006;
Butani et al., 2014; Üstündağ Okur et al., 2014). Furthermore, the oily
phase, then the isopropylmyristate, has characteristics of a transdermal
permeation enhancer (Nokhodchi, 2003), which may have contributed
to the results from ME50 and ME100. Moreover, EM50 showed lower
11K.A. Figueiredo et al. / Pharmacology, Biochemistry and Behavior 131 (2015) 6–12results compared to themicroemulsion. Conventional emulsions have a
relatively large particle size and often exhibit characteristics of release
and transdermal permeation of different drug microemulsion systems,
as shown in Teichmann (2007).
The proportional decrease in the quantity of microemulsion admin-
istered in ME100 group (given that the dose was the same for all
groups) and the consequent reduction of surface area of the skin that
received the microemulsion may have contributed to the slight differ-
ences observed in the percentage of seizure and levels of TBARS
compared to ME50 group (Table 1 and Fig. 1).
The results of this study come from an innovative way to demon-
strate the ability of transdermal microemulsion containing phenobarbi-
tal to reduce epileptic seizures induced by pilocarpine, oxidative stress
and the consequent neuronal damage in experimental animals. Thus,
the use of such a microemulsion may have potential application as
a transdermal release system in antiepileptic therapy, and it may
minimize the inter-individual variation in pharmacokinetics of pheno-
barbital in pediatrics when administered orally (Sweetman, 2007), as
well as facilitate its adherence in chronic use. However, subsequent
pharmacokinetic studies are needed to better assess the differences
observed in relation to the oral route in terms of bioavailability.
5. Conclusion
From the results of this study, it was observed that phenobarbital
incorporated into microemulsion was able to increase the latency for
the installation of seizures, reduce its percentage and number of deaths,
as well as reduce oxidative stress and neuronal damage in the hippo-
campus of mice. These ﬁndings reinforce the hypothesis of the use of
microemulsion containing phenobarbital as nanocarrier with potential
application for transdermal use in the treatment of epilepsy.
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